Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival

Sci Adv. 2018 Sep 12;4(9):eaat7828. doi: 10.1126/sciadv.aat7828. eCollection 2018 Sep.

Abstract

High lethality rates associated with metastatic cancer highlight an urgent medical need for improved understanding of biologic mechanisms driving metastatic spread and identification of biomarkers predicting late-stage progression. Numerous neoplastic cell intrinsic and extrinsic mechanisms fuel tumor progression; however, mechanisms driving heterogeneity of neoplastic cells in solid tumors remain obscure. Increased mutational rates of neoplastic cells in stressed environments are implicated but cannot explain all aspects of tumor heterogeneity. We present evidence that fusion of neoplastic cells with leukocytes (for example, macrophages) contributes to tumor heterogeneity, resulting in cells exhibiting increased metastatic behavior. Fusion hybrids (cells harboring hematopoietic and epithelial properties) are readily detectible in cell culture and tumor-bearing mice. Further, hybrids enumerated in peripheral blood of human cancer patients correlate with disease stage and predict overall survival. This unique population of neoplastic cells provides a novel biomarker for tumor staging, as well as a potential therapeutic target for intervention.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers, Tumor / blood
  • Carcinoma, Pancreatic Ductal / mortality
  • Carcinoma, Pancreatic Ductal / pathology*
  • Cell Fusion
  • Cell Line, Tumor
  • Cell Survival
  • Epithelial Cells / pathology
  • Female
  • Green Fluorescent Proteins / genetics
  • Green Fluorescent Proteins / metabolism
  • Humans
  • Hybrid Cells
  • Karyotyping
  • Macrophages / pathology
  • Male
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Neoplastic Cells, Circulating / pathology*
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology*
  • Tumor Microenvironment
  • Xenograft Model Antitumor Assays

Substances

  • Biomarkers, Tumor
  • Green Fluorescent Proteins